L7 STRUCTURE UPLOADED

=> D L7
L7 HAS NO ANSWERS
L7 STR



G1 O,S
G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> S L7 SSS FULL
FULL SEARCH INITIATED 15:05:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 559 TO ITERATE

100.0% PROCESSED 559 ITERATIONS 430 ANSWERS
SEARCH TIME: 00.00.01

L8 430 SEA SSS FUL L7

=> FILE caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	523.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.62

FILE 'CAPLUS' ENTERED AT 15:05:10 ON 22 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Jun 2004 VOL 140 ISS 26
FILE LAST UPDATED: 21 Jun 2004 (20040621/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8
L9 11 L8

=> d l9 1-11 ibib abs hitstr

L9 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:678692 CAPLUS
DOCUMENT NUMBER: 139:207822
TITLE: Antipruritics
INVENTOR(S): Yasui, Kiyoshi; Morioka, Yasuhide; Hanasaki, Kohji
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 283 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070277	A1	20030828	WO 2003-JP1725	20030218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-41408 A 20020219

Same assignee date not good West - no U.S. counterpart

AB It is intended to provide antipruritics (drugs to control itching, anti-itch agents and drugs to stop itching). It is found out that a compound having a cannabinoid receptor agonist shows an antipruritic effect.

IT **330479-66-8P 330479-67-9P 330479-68-0P**
330479-72-6P 330479-73-7P 330479-74-8P
330479-75-9P 330479-77-1P 330479-78-2P
330479-79-3P 330479-80-6P 330479-81-7P
330479-82-8P 330479-83-9P 330479-84-0P
330479-85-1P 330479-86-2P 330479-87-3P
330479-88-4P 330479-89-5P 330479-90-8P
330479-91-9P 330479-92-0P 330479-93-1P
330479-94-2P 330479-95-3P 330479-96-4P
330479-97-5P 330479-98-6P 330479-99-7P
330480-00-7P 330480-01-8P 330480-02-9P
330480-03-0P 330480-04-1P 330480-05-2P
330480-06-3P 330480-07-4P 330480-08-5P
330480-09-6P 330480-10-9P 330480-11-0P
330480-12-1P 330480-13-2P 330480-14-3P
330480-15-4P 330480-16-5P 330480-17-6P

330480-18-7P 330480-19-8P 330480-20-1P
330480-21-2P 330480-22-3P 330480-23-4P
330480-24-5P 330480-25-6P 330480-26-7P
330480-27-8P 330480-28-9P 330480-29-0P
330480-30-3P 330480-31-4P 330480-32-5P
330480-33-6P 330480-34-7P 330480-35-8P
330480-36-9P 330480-37-0P 330480-38-1P
330480-39-2P 330480-40-5P 330480-41-6P
330480-42-7P 330480-43-8P 330480-44-9P
330480-45-0P 330480-46-1P 330480-47-2P
330480-48-3P 330480-49-4P 330480-50-7P
330480-51-8P 330480-52-9P 330480-53-0P
330480-54-1P 330480-55-2P 330480-56-3P
330480-57-4P 330480-58-5P 330480-59-6P
330480-60-9P 330480-61-0P 330480-62-1P
330480-63-2P 330480-64-3P 330480-65-4P
330480-66-5P 330480-67-6P 330480-68-7P
330480-69-8P 330480-70-1P 330480-74-5P
330480-75-6P 330480-76-7P 330480-77-8P
330480-78-9P 330480-79-0P 330480-80-3P
330480-81-4P 330480-82-5P 330480-83-6P
330480-84-7P 330480-85-8P 330480-86-9P
330480-87-0P 330480-88-1P 330480-89-2P
330480-90-5P 330480-91-6P 330480-92-7P
330480-93-8P 330480-94-9P 330480-95-0P
330480-96-1P 330480-97-2P 330480-98-3P
330480-99-4P 330481-00-0P 330481-01-1P
330481-02-2P 330481-03-3P 330481-04-4P
330481-05-5P 330481-06-6P 330481-07-7P
330481-08-8P 330481-09-9P 330481-10-2P
330481-11-3P 330481-12-4P 330481-13-5P
330481-14-6P 330481-15-7P 330481-16-8P
330481-17-9P 330481-18-0P 330481-19-1P
330481-20-4P 330481-21-5P 330481-22-6P
330481-23-7P 330481-24-8P 330481-25-9P
330481-26-0P 330481-27-1P 330481-28-2P
330481-29-3P 330481-30-6P 330481-31-7P
330481-32-8P 330481-33-9P 330481-34-0P
330481-35-1P 330481-36-2P 330481-37-3P
330481-38-4P 330481-39-5P 330481-40-8P
330481-41-9P 330481-42-0P 330481-43-1P
330481-44-2P 330481-45-3P 330481-46-4P
330481-47-5P 330481-48-6P 330481-49-7P
330481-50-0P 330481-51-1P 330481-52-2P
330481-53-3P 330481-54-4P 330481-55-5P
330481-56-6P 330481-57-7P 330481-58-8P
330481-59-9P 330481-60-2P 330481-61-3P
330481-62-4P 330481-63-5P 330481-64-6P
330481-65-7P 330481-66-8P 330481-67-9P
330481-68-0P 330481-69-1P 330481-70-4P
330481-71-5P 330481-72-6P 330481-73-7P
330481-74-8P 330481-75-9P 330481-76-0P
330481-77-1P 330481-78-2P 330481-79-3P
330481-80-6P 330481-81-7P 330481-82-8P
330481-83-9P 330481-84-0P 330481-85-1P
330481-86-2P 330481-87-3P 330481-88-4P
330481-89-5P 330481-90-8P 330481-91-9P
330481-92-0P 330481-93-1P 330481-94-2P
330481-95-3P 330481-96-4P 330481-97-5P
330481-98-6P 330481-99-7P 330482-00-3P

330482-01-4P 330482-02-5P 330482-03-6P
330482-08-1P 330482-09-2P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cannabinoid receptor agonist as an antipruritics)

RN 330479-66-8 CAPLUS
CN 2H-1,3-Thiazin-2-imine, tetrahydro-5,5-dimethyl-N-[2-(1-methylethyl)phenyl]-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 330479-67-9 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 330479-68-0 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbothioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, S-ethyl ester (9CI) (CA INDEX NAME)



RN 330479-72-6 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbothioic acid, dihydro-2-[[(2-methoxyphenyl)methyl]imino]-5,5-dimethyl-, S-ethyl ester (9CI) (CA INDEX NAME)



RN 330479-73-7 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-2-[[(2-methoxyphenyl)methyl]imino]-5,5-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 330479-74-8 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbothioic acid, dihydro-2-[[2-(2-methoxyphenyl)ethyl]imino]-5,5-dimethyl-, S-ethyl ester (9CI) (CA INDEX NAME)



RN 330479-75-9 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-2-[[2-(2-methoxyphenyl)ethyl]imino]-5,5-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 330479-77-1 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbothioic acid, dihydro-5,5-dimethyl-2-(phenylimino)-, S-ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:716259 CAPLUS
DOCUMENT NUMBER: 137:247707
TITLE: Preparation of 2-(aryl or heteroarylalkylimino)-1,3-thiazine derivatives having affinity for cannabinoid receptor of type 2 and medicinal compositions containing them
INVENTOR(S): Kai, Hiroyuki; Murashi, Takami; Tomida, Minoru
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072562	A1	20020919	WO 2002-JP1229	20020214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1375489	A1	20040102	EP 2002-700580	20020214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004116326	A1	20040617	US 2003-470388	20030728

PRIORITY APPLN. INFO.: JP 2001-65386 A 20010308
WO 2002-JP1229 W 20020214
OTHER SOURCE(S): MARPAT 137:247707
GI



I

assignee
no. non provisional

AB Compds. represented by the formula [I; R1 = (un)substituted heterocyclic group, C(:Z)W-R4 (wherein Z, W = O, S; R4 = optionally substituted alkyl, alkenyl, or alkynyl); R2, R3 = H, (un)substituted alkyl, alkoxyalkyl, aminoalkyl, or cycloalkyl; or R2 and R3 together represents (un)substituted alkylene optionally containing heteroatoms; m = an integer of 0-2; A = (un)substituted aromatic carbon ring group; provided that when R1 is C(:Z)W-R4 (wherein Z, W = O, S; R4 = unsubstituted alkyl), R2 and R3 together represent an alkylene optionally containing heteroatoms] or prodrugs thereof or pharmacol. acceptable salts thereof or solvate thereof are prepared These compds. have a specific affinity for cannabinoid receptor of type 2 and are useful as agonists and/or antagonists, in particular agonists of cannabinoid type 2 receptor (CB2R) for the prevention or treatment of CB2R-related diseases, in particular as antiinflammatory agents. Thus, 0.05 g NaH was added to a mixture of 0.26 g 2-(2-isopropylphenyl)imino-5,5-dimethyl-1,3-thiazine, 0.24 g 5-trifluoromethyl-2-chloropyridine, and 3 mL DMF under ice-cooling and stirred at room temperature for 2 h to give 2-(2-isopropylphenyl)imino-3-(5-trifluoromethyl-2-pyridyl)-5,5-dimethyl-1,3-thiazine. 2-[[[2-(2-Isopropylphenyl)imino-5,5-diethyl-1,3-thiazin-3-yl]thiocarbonyl]thio]acetic acid tert-Bu ester inhibited the binding of [3H]CP55940 to human CB1R and CB2R with Ki of >5,000 and 0.3 nM, resp.

IT **459872-13-0P 459872-14-1P 459872-15-2P**
459872-16-3P 459872-17-4P 459872-18-5P
459872-19-6P 459872-20-9P 459872-21-0P
459872-22-1P 459872-23-2P 459872-24-3P
459872-25-4P 459872-26-5P 459872-27-6P
459872-28-7P 459872-29-8P 459872-30-1P
459872-31-2P 459872-32-3P 459872-33-4P
459872-35-6P 459872-37-8P 459872-38-9P
459872-40-3P 459872-42-5P 459872-44-7P
459872-46-9P 459872-48-1P 459872-49-2P
459872-50-5P 459872-51-6P 459872-52-7P
459872-54-9P 459872-57-2P 459872-58-3P
459872-59-4P 459872-60-7P 459872-62-9P
459872-64-1P 459872-66-3P 459872-68-5P
459872-70-9P 459872-72-1P 459872-74-3P
459872-76-5P 459872-78-7P 459872-80-1P
459872-82-3P 459872-84-5P 459872-86-7P
459872-88-9P 459872-90-3P 459872-92-5P
459872-94-7P 459872-96-9P 459872-98-1P
459873-00-8P 459873-01-9P 459873-02-0P
459873-04-2P 459873-06-4P 459873-08-6P
459873-10-0P 459873-11-1P 459873-13-3P
459873-15-5P 459873-17-7P 459873-19-9P
459873-21-3P 459873-23-5P 459873-25-7P
459873-27-9P 459873-29-1P 459873-31-5P
459873-33-7P 459873-35-9P 459873-37-1P
459873-39-3P 459873-41-7P 459873-42-8P
459873-43-9P 459873-44-0P 459873-45-1P
459873-46-2P 459873-47-3P 459873-48-4P
459873-49-5P 459873-50-8P 459873-51-9P
459873-52-0P 459873-53-1P 459873-54-2P
459873-55-3P 459873-56-4P 459873-57-5P
459873-58-6P 459873-59-7P 459873-60-0P
459873-61-1P 459873-62-2P 459873-63-3P
459873-64-4P 459873-65-5P 459873-66-6P
459873-71-3P 459873-72-4P 459873-73-5P
459873-74-6P 459873-75-7P 459873-76-8P
459873-77-9P 459873-78-0P 459873-79-1P

459873-80-4P 459873-81-5P 459873-82-6P
459873-83-7P 459873-84-8P 459873-85-9P
459873-86-0P 459873-87-1P 459873-88-2P
459873-89-3P 459873-90-6P 459873-91-7P
459873-92-8P 459873-93-9P 459873-94-0P
459873-95-1P 459873-96-2P 459873-97-3P
459873-98-4P 459873-99-5P 459874-00-1P
459874-01-2P 459874-02-3P 459874-03-4P
459874-04-5P 459874-05-6P 459874-06-7P
459874-07-8P 459874-08-9P 459874-09-0P
459874-10-3P 460091-50-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (aryl or heteroarylalkylimino)thiazine derivs. having affinity for cannabinoid receptor of type 2 and medicinal compns. containing them)

RN 459872-13-0 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 459872-14-1 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, 2-propynyl ester (9CI) (CA INDEX NAME)



RN 459872-15-2 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, cyanomethyl ester (9CI) (CA INDEX NAME)



RN 459872-16-3 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, methoxymethyl ester (9CI) (CA INDEX NAME)



RN 459872-17-4 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, 2-butenyl ester (9CI) (CA INDEX NAME)



RN 459872-18-5 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, 3-methyl-2-butenyl ester (9CI) (CA INDEX NAME)



RN 459872-19-6 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, 3-butenyl ester (9CI) (CA INDEX NAME)



RN 459872-20-9 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, 2-oxopropyl ester (9CI) (CA INDEX NAME)



RN 459872-21-0 CAPLUS
CN Acetic acid, [[[dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-2H-1,3-thiazin-3(4H)-yl]thioxomethyl]thio]- (9CI) (CA INDEX NAME)



RN 459872-22-1 CAPLUS
CN Acetic acid, [[[dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-2H-1,3-thiazin-3(4H)-yl]thioxomethyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 459872-23-2 CAPLUS
CN Acetic acid, [[[dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-2H-1,3-thiazin-3(4H)-yl]thioxomethyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 459872-24-3 CAPLUS
CN Acetic acid, [[[dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-2H-1,3-thiazin-3(4H)-yl]thioxomethyl]thio]-, propyl ester (9CI) (CA INDEX NAME)



RN 459872-25-4 CAPLUS
CN Acetic acid, [[[dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-2H-1,3-thiazin-3(4H)-yl]thioxomethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 459872-26-5 CAPLUS
CN Acetic acid, [[[dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-2H-1,3-thiazin-3(4H)-yl]thioxomethyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 459872-27-6 CAPLUS
CN Acetic acid, [[[dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-2H-1,3-thiazin-3(4H)-yl]thioxomethyl]thio]-, ethenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:208257 CAPLUS
DOCUMENT NUMBER: 134:237483
TITLE: Preparation of 2-imino-1,3-thiazine derivatives as CB2R antagonists
INVENTOR(S): Hanasaki, Koji; Murashi, Takami; Kai, Hiroyuki
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019807	A1	20010322	WO 2000-JP6185	20000911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000068773	A5	20010417	AU 2000-68773	20000911
EP 1219612	A1	20020703	EP 2000-957083	20000911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-260780 A 19990914
WO 2000-JP6185 W 20000911

OTHER SOURCE(S): MARPAT 134:237483
GI

prosecution



I



II

AB Title compds. [I; wherein R1 represents optionally substituted alkylene; R2 represents hydrogen, alkyl, a group represented by the formula C(:R5)R6 (wherein R5 represents O or S; and R6 represents alkyl, alkoxy, alkylthio, etc.) or a group represented by the formula SO2R7 (wherein R7 represents alkyl, etc.); m is an integer of from 0 to 2; and A represents optionally substituted aryl, etc.] and pharmaceutically acceptable salts are prepared Title compds. bind selectively to cannabinoid 2 receptor (CB2R) and thus exhibit CB2R antagonism. Thus, the title compound II was prepared and tested.

IT **330479-66-8P 330479-67-9P 330479-68-0P**
330479-72-6P 330479-73-7P 330479-74-8P
330479-75-9P 330479-77-1P 330479-78-2P
330479-79-3P 330479-80-6P 330479-81-7P
330479-82-8P 330479-83-9P 330479-85-1P
330479-86-2P 330479-87-3P 330479-88-4P
330479-89-5P 330479-90-8P 330479-91-9P
330479-92-0P 330479-93-1P 330479-94-2P
330479-95-3P 330479-96-4P 330479-97-5P
330479-98-6P 330479-99-7P 330480-00-7P
330480-01-8P 330480-02-9P 330480-03-0P
330480-04-1P 330480-05-2P 330480-06-3P
330480-07-4P 330480-08-5P 330480-09-6P
330480-10-9P 330480-14-3P 330480-15-4P
330480-16-5P 330480-19-8P 330480-20-1P
330480-22-3P 330480-26-7P 330480-27-8P
330480-28-9P 330480-29-0P 330480-31-4P
330480-32-5P 330480-33-6P 330480-34-7P
330480-36-9P 330480-37-0P 330480-39-2P
330480-40-5P 330480-41-6P 330480-42-7P
330480-43-8P 330480-44-9P 330480-47-2P
330480-48-3P 330480-49-4P 330480-50-7P
330480-51-8P 330480-52-9P 330480-53-0P
330480-54-1P 330480-55-2P 330480-56-3P
330480-57-4P 330480-58-5P 330480-59-6P
330480-60-9P 330480-61-0P 330480-62-1P
330480-63-2P 330480-64-3P 330480-65-4P
330480-66-5P 330480-67-6P 330480-68-7P
330480-69-8P 330480-70-1P 330480-74-5P
330480-75-6P 330480-76-7P 330480-77-8P
330480-78-9P 330480-80-3P 330480-81-4P
330480-82-5P 330480-83-6P 330480-84-7P
330480-85-8P 330480-86-9P 330480-87-0P
330480-88-1P 330480-89-2P 330480-90-5P
330480-91-6P 330480-92-7P 330480-93-8P

330480-94-9P 330480-95-0P 330480-96-1P
330480-97-2P 330480-98-3P 330480-99-4P
330481-00-0P 330481-01-1P 330481-02-2P
330481-03-3P 330481-04-4P 330481-05-5P
330481-06-6P 330481-07-7P 330481-08-8P
330481-09-9P 330481-10-2P 330481-11-3P
330481-12-4P 330481-13-5P 330481-14-6P
330481-15-7P 330481-16-8P 330481-17-9P
330481-18-0P 330481-19-1P 330481-20-4P
330481-21-5P 330481-22-6P 330481-23-7P
330481-24-8P 330481-25-9P 330481-26-0P
330481-27-1P 330481-28-2P 330481-29-3P
330481-30-6P 330481-31-7P 330481-32-8P
330481-33-9P 330481-34-0P 330481-35-1P
330481-36-2P 330481-37-3P 330481-38-4P
330481-39-5P 330481-40-8P 330481-41-9P
330481-42-0P 330481-43-1P 330481-44-2P
330481-45-3P 330481-46-4P 330481-47-5P
330481-48-6P 330481-49-7P 330481-50-0P
330481-51-1P 330481-52-2P 330481-53-3P
330481-54-4P 330481-55-5P 330481-56-6P
330481-57-7P 330481-58-8P 330481-59-9P
330481-60-2P 330481-61-3P 330481-62-4P
330481-63-5P 330481-64-6P 330481-65-7P
330481-66-8P 330481-67-9P 330481-68-0P
330481-69-1P 330481-70-4P 330481-71-5P
330481-72-6P 330481-73-7P 330481-74-8P
330481-75-9P 330481-76-0P 330481-77-1P
330481-78-2P 330481-79-3P 330481-80-6P
330481-81-7P 330481-82-8P 330481-83-9P
330481-84-0P 330481-85-1P 330481-86-2P
330481-87-3P 330481-88-4P 330481-89-5P
330481-90-8P 330481-91-9P 330481-92-0P
330481-93-1P 330481-94-2P 330481-95-3P
330481-96-4P 330481-97-5P 330481-98-6P
330481-99-7P 330482-00-3P 330482-01-4P
330482-02-5P 330482-03-6P 330482-08-1P
330482-09-2P 330482-21-8P 330482-22-9P
330482-23-0P 330482-24-1P 330482-25-2P
330482-26-3P 330482-27-4P 330482-28-5P
330482-29-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and effect of 2-imino-1,3-thiazine derivs. as CB2R antagonists)

RN 330479-66-8 CAPLUS
CN 2H-1,3-Thiazin-2-imine, tetrahydro-5,5-dimethyl-N-[2-(1-methylethyl)phenyl]-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 330479-67-9 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 330479-68-0 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbothioic acid, dihydro-5,5-dimethyl-2-[[2-(1-methylethyl)phenyl]imino]-, S-ethyl ester (9CI) (CA INDEX NAME)



RN 330479-72-6 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbothioic acid, dihydro-2-[[(2-methoxyphenyl)methyl]imino]-5,5-dimethyl-, S-ethyl ester (9CI) (CA INDEX NAME)



RN 330479-73-7 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carbodithioic acid, dihydro-2-[[(2-methoxyphenyl)methyl]imino]-5,5-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:552346 CAPLUS
DOCUMENT NUMBER: 113:152346
TITLE: Reaction of isocyanates with 2-(phenylimino)tetrahydro-1,3-thiazines and -oxazines
AUTHOR(S): Nabeya, Aiko; Endo, Tadatoshi; Saito, Jun; Mitsuishi, Takatoshi; Inahara, Masashi
CORPORATE SOURCE: Sch. Dent. Med., Tsurumi Univ., Yokohama, Japan
SOURCE: Journal of Heterocyclic Chemistry (1990), 27(4), 903-7
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:152346
GI



AB Reaction of isocyanates, e.g., RNCO (R = Ph, CH2Ph), with thiazines and oxazines, e.g. I (R1, R2 = H, Me; X = O, S), occurs at the ring nitrogen first to give the carbamoylated compound, e.g. II, and then the carbamoyl group migrates to the exo nitrogen to give, e.g. III. Though the carbamoylated thiazines II and III exist in equilibrium with the isocyanate and the thiazine in solution, crossover expts. showed that the rearrangement proceeded by an intramol. mechanism.

IT **13677-18-4P 129663-41-8P 129663-50-9P 129663-51-0P 129663-52-1P 129663-53-2P 129663-58-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and intramol. rearrangement of)

RN 13677-18-4 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxamide, dihydro-N-phenyl-2-(phenylimino)- (9CI) (CA INDEX NAME)



RN 129663-41-8 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxamide, dihydro-6-methyl-N-phenyl-2-(phenylimino)- (9CI) (CA INDEX NAME)

(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 129663-58-7 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxamide, dihydro-4-methyl-N-phenyl-2-(phenylimino)- (9CI) (CA INDEX NAME)



L9 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1978:579076 CAPLUS
DOCUMENT NUMBER: 89:179076
TITLE: Energetic and kinetic studies of electron impact induced ortho-substitution reactions of 2-arylaminothiazines
AUTHOR(S): Bujtas, G.; Tamas, J.
CORPORATE SOURCE: Cent. Res. Inst. Chem., Hung. Acad. Sci., Budapest, Hung.
SOURCE: Advances in Mass Spectrometry (1978), 7B, 1251-5
CODEN: AMSPAH; ISSN: 0568-000X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Abundance of [M-R]+ and [M-R]+/[M]+ ratios were determined for I (R = H, Me, Cl; R1 = H, Me, SO2Me, CO2Et) and II (R = Me, Cl; R1 = Me, SO2Me, CO2Et) via mass spectral data.

IT **36157-27-4**
RL: PRP (Properties)
(mass spectra of)

RN 36157-27-4 CAPLUS

CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, 2-[(2,6-dichlorophenyl)imino]dihydro-, ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1978:441683 CAPLUS

DOCUMENT NUMBER: 89:41683

TITLE: Carbon-13 NMR investigation of 2-arylaminothiazolines and analogous thiazines, thiazepines and their amides

AUTHOR(S): Sohar, P.; Feher, G.; Toldy, L.

CORPORATE SOURCE: Res. Inst. Pharm. Chem., Budapest, Hung.

SOURCE: Organic Magnetic Resonance (1978), 11(1), 9-11
CODEN: ORMRBD; ISSN: 0030-4921

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The 13C NMR spectra of 2-arylaminothiazoline, -thiazine, and -thiazepine derivs., and some N-substituted isomeric pairs were studied. The previously ambiguous structures of some individual isomers were established, and the structures of some N-unsubstituted tautomeric compds. were determined

IT **36157-27-4 54708-10-0 67057-44-7**
RL: PRP (Properties)

(structure of, carbon-13 NMR study of)
RN 36157-27-4 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, 2-[(2,6-dichlorophenyl)imino]dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 54708-10-0 CAPLUS
CN 2H-1,3-Thiazin-2-imine, 3-acetyl-N-(2,6-dimethylphenyl)tetrahydro- (9CI) (CA INDEX NAME)



RN 67057-44-7 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, 2-[(2,6-dimethylphenyl)imino]dihydro-, ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:106189 CAPLUS
DOCUMENT NUMBER: 82:106189
TITLE: Amidines and related compounds. 6. Structure-activity relations of antihypertensive and antisecretory agents related to clonidine
AUTHOR(S): Jen, Timothy; Van Hoeven, Helene; Groves, William; McLean, Richard A.; Loev, Bernard
CORPORATE SOURCE: Res. Dev. Div., Smith Kline and French Lab., Philadelphia, PA, USA
SOURCE: Journal of Medicinal Chemistry (1975), 18(1), 90-9
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB A series of 67 analogs of clonidine [4205-90-7] was prepared and tested orally for antihypertensive activity in hypertensive rats and dogs and antisecretory activity in fistula rats. 2-(2,6-Dimethylphenylimino)imidazolidine (I) [4859-06-7] and 2-(2,6-dichlorophenylimino)pyrrolidine (II) [21656-98-4] are effective antisecretory agents with minimal antihypertensive activity. Structure-activity relations are discussed.
IT **54708-10-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antihypertensive and antisecretory activity of)
RN 54708-10-0 CAPLUS
CN 2H-1,3-Thiazin-2-imine, 3-acetyl-N-(2,6-dimethylphenyl)tetrahydro- (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1973:96733 CAPLUS
DOCUMENT NUMBER: 78:96733
TITLE: Structure of carbethoxy and acetyl derivatives of 2-arylaminothiazolines, -thiazines, and -3-aryl-2-iminothiazolidines
AUTHOR(S): Sohar, P.; Toldy, L.; Farago, K.
CORPORATE SOURCE: Res. Inst. Pharm. Chem., Budapest, Hung.
SOURCE: Acta Chimica Academiae Scientiarum Hungaricae (1973), 75(2), 111-22
CODEN: ACASA2; ISSN: 0001-5407
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Acylation products of I and II were shown by NMR and ir spectra to be the amino or imino N-derivs. (III and IV). III and IV studied included (R, and R1 given): 2,6-Me2C6H3, CO2Et; 2,6-Cl2C6H3, CO2Et; 4,2,6-BrMe2C6H2, COCH2Cl.
IT **36157-27-4**
RL: PROC (Process)
(ir spectra and NMR of)
RN 36157-27-4 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, 2-[(2,6-dichlorophenyl)imino]dihydro-, ethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:126938 CAPLUS
DOCUMENT NUMBER: 76:126938
TITLE: Structure determination of amides of 2-arylamino-2-thiazolines and the analogous thiazines. Acyl migration
AUTHOR(S): Toth, Gabor; Tamas, Jozsef; Toldy, Lajos
CORPORATE SOURCE: Gyogyszerkut. Intez., Budapest, Hung.
SOURCE: Magyar Kemikusok Lapja (1971), 26(11), 561-70
CODEN: MGKLAL; ISSN: 0025-0163
DOCUMENT TYPE: Journal
LANGUAGE: Hungarian
GI For diagram(s), see printed CA Issue.
AB Acylation of 2-arylamino-2-thiazolines or 2-arylamino-5,6-dihydro-4H-1,3-thiazines gave endo (I) and exo (II) isomers (x = 1,2; R1 = 2,6-xylyl, 4-bromo-2,6-xylyl, 2,6-dichlorophenyl, 2,4-dibromo-o-biphenylyl, 3-nitro-2,6-xylyl, 4-bromo-3-nitro-2,6-xylyl, mesityl, 3-bromomesityl; R2 = Ac, Bz, COC6H4Me-p, COC6H4Et-p, COC6H4OMe-p, hex 5f COC6H4Cl-p, COC6H4Cl-o, CO2Et, SO2Me). I (R2 = SO2Me) and II (R2 = SO2Me) and I (R2 = Bz) and II (R2 = Bz), resp., were distinguished by comparing their PMR spectra with those of their salts. The structures of I (R2 = Ac, CO2Et) and II (R2 = Ac, CO2Et) were determined by their mass spectra. II (R2 = SO2Me) rearranged thermally to I (R2 = SO2Me) via the cation MeS+O2.
IT **36157-27-4P 36157-30-9P 36157-32-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36157-27-4 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, 2-[(2,6-dichlorophenyl)imino]dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 36157-30-9 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxylic acid, 2-[(3-bromo-2,4,6-trimethylphenyl)imino]dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 36157-32-1 CAPLUS
CN 2H-1,3-Thiazin-2-imine, 3-acetyl-N-(3-bromo-2,4,6-trimethylphenyl)tetrahydro- (9CI) (CA INDEX NAME)



L9 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1967:94976 CAPLUS
DOCUMENT NUMBER: 66:94976
TITLE: Formation and rearrangement of esters. LXXII. 2-Aryl (or aralkyl or alkyl)aminotetrahydro-4H-1,3-thiazines or 2-aryl (or aralkyl or alkyl) amino-5,6-dihydro-4H-1,3-thiazines and their derivatives
AUTHOR(S): Cherbuliez, Emile; Baehler, Bruno; Espejo, O.; Jindra, H.; Willhalm, B.; Rabinowitz, Joseph
CORPORATE SOURCE: Univ. Geneva, Geneva, Switz.
SOURCE: Helvetica Chimica Acta (1967), 50(1), 331-46
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 66:94976

AB cf. CA 66, 75767b. Aryl (or aralkyl) isothiocyanates, RNCS, were treated with 3-aminopropanol (I) to give thioureas, RNHCSNH(CH2)3OH, which are either 2-(R-substituted-imino)tetrahydro-4H-1,3-thiazines or 2-(R-substituted-amino)-5,6-dihydro-4H-1,4-thiazines. The structures of the hydrothiazines prepared from I and p-fluorophenyl isothiocyanate, p-bromophenyl isothiocyanate, p-fluorobenzyl isothiocyanate, ethyl isothiocyanate, or butyl isothiocyanate were established by comparing their N.M.R. spectra with those of 2-methyl-5,6-dihydro-4H-1,3-thiazine, in which the C:N bond is endo-cyclic, and of 3-methyl-2-phenyliminotetrahydro-4H-1,3-thiazine, in which the C:N bond is exo-cyclic. When R is an aryl group, the C:N bond is exo-cyclic, apparently due to resonance stabilization, while when R is aralkyl or alkyl, the C:N bond is endo-cyclic. Treatment of 2-aryliminotetrahydro-4H-1,3-thiazines with an RNCO gives the corresponding carbamoyl derivs. 3-Benzoyl-2-phenyliminotetrahydro-4H-1,3-thiazine was prepared by treating BzCl with 2-phenyliminotetrahydro-4H-1,3-thiazine in the presence of a tertiary base.

IT **13677-18-4P 13677-21-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and N.M.R. of)
RN 13677-18-4 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxamide, dihydro-N-phenyl-2-(phenylimino)- (9CI)
(CA INDEX NAME)



RN 13677-21-9 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxanilide, 2-[(p-fluorophenyl)imino]-5,6-dihydro-
(8CI) (CA INDEX NAME)



IT **13677-19-5P 13677-20-8P 13677-22-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 13677-19-5 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxamide, N-benzyldihydro-2-(phenylimino)- (8CI)
(CA INDEX NAME)



RN 13677-20-8 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxamide, N-butyldihydro-2-(phenylimino)- (8CI)
(CA INDEX NAME)



RN 13677-22-0 CAPLUS
CN 2H-1,3-Thiazine-3(4H)-carboxanilide, 2-[(p-bromophenyl)imino]-5,6-dihydro- (8CI) (CA INDEX NAME)



L9 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1964:432422 CAPLUS
DOCUMENT NUMBER: 61:32422
ORIGINAL REFERENCE NO.: 61:5644c-f
TITLE: Formation of 3-substituted 2-thioxo-4-oxohexahydro-1,3-diazines and 2-(substituted imino)-6-oxo-1,3-thiazanes from 1-sub-stituted 3-carboxyethylthioureas and interconversion of both cyclic systems.
AUTHOR(S): Prosen, A.; Stanovnik, B.; Tisler, M.
CORPORATE SOURCE: Univ. Ljubl-jana, Yugoslavia
SOURCE: Journal of Organic Chemistry (1964), 29(6), 1623-4
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 61:32422
GI For diagram(s), see printed CA Issue.
AB The interconversion of 3-substituted 2-thioxo-4-oxohexahydro-1,3diazines (I) and 2-(substituted imino)-6-oxo-1,3-thiazanes (II) (R' = Ac or H) was reported. When the cyclization of 3-carboxyethylthioureas was carried out in Ac2O at 90-5° the chief product was II; however, I could be isolated from the mother liquor. Ratios of I-II were obtained when R was o-tolyl, p-MeOC6H4, o-ClC6H4, m-ClC6H4, and p-ClC6H4. Reaction time also greatly influenced the yields of I and II. Ac2O transformed I into II under the same conditions as for the direct cyclization. However, treatment of II with dilute AcOH or with C5H5N gave I; with the acetylated products the same conversion occurred. The interconversion of both ring systems was followed spectrophotometrically as both systems were readily distinguished on the basis of their ultraviolet spectra. Thus, the formation of I (R = o-tolyl) from the corresponding II was followed in 10% AcOH at 60°; the optimum conversion of 88% was achieved after 80 min. However, I (R = o-tolyl) was changed into II with Ac2O after 120 min. at 60° for an 83% conversion.
IT **91446-56-9**, 6H-1,3-Thiazin-6-one, 3-acetyl-2-[(m-

chlorophenyl)imino]tetrahydro- **91807-37-3,** 6H-1,3-Thiazin-6-one, 3-acetyltetrahydro-2-[(p-methoxyphenyl)imino]- **93350-74-4,** 6H-1,3-Thiazin-6-one, 3-acetyltetrahydro-2-(p-tolylimino)- (preparation of)

RN 91446-56-9 CAPLUS

CN 6H-1,3-Thiazin-6-one, 3-acetyl-2-[(m-chlorophenyl)imino]tetrahydro- (7CI) (CA INDEX NAME)



RN 91807-37-3 CAPLUS

CN 6H-1,3-Thiazin-6-one, 3-acetyltetrahydro-2-[(p-methoxyphenyl)imino]- (7CI) (CA INDEX NAME)



RN 93350-74-4 CAPLUS

CN 6H-1,3-Thiazin-6-one, 3-acetyltetrahydro-2-(p-tolylimino)- (7CI) (CA INDEX NAME)